HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial

HaemaLogiX has treated the first patient with its KMCAR T-cell therapy as part of the Phase I KOALA clinical trial for relapsed or refractory kappa-restricted multiple myeloma.

The post HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.